Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer.Ravi A. Madan, James L. Gulley, Marc R. Theoret et al.|Journal of Clinical Oncology|2016Cited by 6
Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact.Ravi A. Madan, James L. Gulley, Renee N. Donahue et al.|Journal of Clinical Oncology|2016Cited by 1